Search Results

DisperSol Technologies and Catalent announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.

DisperSol Technologies LLC announced that it is promoting Chris Brough from Vice President Technology to Chief Technology Officer effective immediately.

DisperSol Technologies LLC announced that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.

DisperSol Technologies LLC announced today that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies.

DisperSol Technologies, LLC, a specialty pharmaceutical company, today announced the appointment of Tim Scott as president and chief executive officer (CEO) of the company.

• Augurex’s SPINEstat® (Anti-14-3-3eta Multiplex for axial spondyloarthritis) test has been selected as a finalist in the ADLM 2026 Disruptive Technology Award, one of laboratory medicine’s most competitive recognition programs. • Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, with a dedicated finalist kiosk on the Expo Floor July 28–30. • The recognition underscores Augurex’s leadership in developing biomarker-driven diagnostics that address critical unmet needs across autoimmune and inflammatory diseases.

Collaboration Expected to Expand the Commercialization of Stem Cell Aesthetic and Anti-Aging Products Through an AI-Enabled Community Healthcare and Senior Care Network in China